Skip to main content

Table 1 Clinico-pathological characteristics at primary diagnosis and genotype distribution

From: The BCL2-938 C > A promoter polymorphism is associated with risk group classification in children with acute lymphoblastic leukemia

  All BCL2−938 genotype Pvalue
AC / AA CC
n (%) 182 141 (77.5) 41 (22.5)  
Mean age (years ± SD) 6.5 ± 4.6 6.3 ± 4.5 7.1 ± 4.6 0.298
Gender (male/female) 111/71 83/58 28/13 0.276
Relapse
no 137 105 (76.7) 32 (23.3) 0.640
yes 45 36 (80.0) 9 (20.0)
HSCT     
no 119 97 (81.5) 22 (18.5) 0.073
yes 63 44 (69.9) 19 (30.1)
Relapse after HSCT (n = 63)
no 40 26 (65.0) 14 (35.0) 0.270
yes 23 18 (78.3) 5 (21.7)
Risk Group Classification
standard 67 59 (88.1) 8 (11.9)  
medium 72 53 (73.6) 19 (26.4) 0.008
high 43 29 (67.4) 14 (32.6)  
Prednisone response (n = 174)
good 160 129 (80.6) 31 (19.4) 0.148
poor 14 9 (64.3) 5 (35.7)
Molecular genetics (n = 176)
no aberration 121 94 (77.7) 27 (22.3) 0.627
BCR/ABL fusion 13 9 (69.2) 4 (30.8)
TEL/AML rearrangement 35 28 (80.0) 7 (20.0)
MLL/AF4 rearrangement 3 3 0
TCF3/PBX1 rearrangement 1 1 0
chromosomal 9 deletion 1 1 0
hyperdiploidity 2 2 0  
  1. HSCT, Hematopoietic stem cell transplantation.